Workflow
AbbVie expects $2.7 billion R&D charge in third quarter
艾伯维艾伯维(US:ABBV) Reuters·2025-10-04 04:16

Drugmaker AbbVie in a regulatory filing on Friday said it expects third-quarter earnings to include a $2.7 billion charge related to in-process research and development (IPR&D) expenses. ...